Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone, a retrospective study

Mycobacterium avium complex (MAC) bacteria, i.e. M. avium , M. intracellulare , M. chimaera and related species, can cause severe pulmonary disease (MAC-PD), especially in patients with chronic pulmonary diseases, like COPD and bronchiectasis [1, 2]. Footnotes This manuscript has recently been accepted for publication in the ERJ Open Research . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article. Conflict of interest: Dr. Zweijpfenning reports grants from Insmed, outside the submitted work. Conflict of interest: Dr. Kops has nothing to disclose. Conflict of interest: Dr. Boeree has nothing to disclose. Conflict of interest: Dr. Kuipers has nothing to disclose. Conflict of interest: Dr. van Ingen has nothing to disclose. Conflict of interest: Dr. Hoefsloot has nothing to disclose. Conflict of interest: Dr. magis-escurra has nothing to disclose.